- Home
- NBIX vs BAX Comparison
NBIX vs BAX Comparison
Compare NBIX & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBIX | BAX |
|---|---|---|
| Founded | 1992 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 9.4B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | NBIX | BAX |
|---|---|---|
| Price | $155.51 | $18.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 10 |
| Target Price | ★ $173.79 | $25.67 |
| AVG Volume (30 Days) | 969.9K | ★ 8.3M |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 0.22% |
| EPS Growth | ★ 12.44 | N/A |
| EPS | ★ 4.19 | N/A |
| Revenue | $2,682,700,000.00 | ★ $11,023,000,000.00 |
| Revenue This Year | $23.76 | $5.20 |
| Revenue Next Year | $18.01 | $2.02 |
| P/E Ratio | $37.10 | ★ N/A |
| Revenue Growth | ★ 19.61 | 3.90 |
| 52 Week Low | $84.23 | $17.40 |
| 52 Week High | $157.67 | $37.74 |
Technical Indicators
Market Signals| Indicator | NBIX | BAX |
|---|---|---|
| Relative Strength Index (RSI) | 64.81 | 43.20 |
| Support Level | $150.26 | $18.33 |
| Resistance Level | $154.35 | $19.17 |
| Average True Range (ATR) | 4.16 | 0.54 |
| MACD | 1.07 | 0.21 |
| Stochastic Oscillator | 93.25 | 63.23 |
Price Performance
Historical ComparisonAbout NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.